

Comparison between treatment options in patients over the age of 70 years with AML



Cohort

980 Acute myeloid leukemia (AML) patients; median age 75.6 (70-95.7) years



Treatment options

1 - High-intensity (daunorubicin/cytarabine or equivalent)	360 (36.7%)
2 - Hypomethylating agent (HMA)	255 (26.0%)
3 - Low-intensity (low-dose cytarabine or similar without hypomethylating agents)	91 (9.3%)
4 - Supportive care therapy (including hydroxyurea)	274 (28.0%)



Median follow-up 25 months
Median overall survival of the entire cohort 7.1 months



Results

Median overall survival

1 - High-intensity	10.8 months
2 - HMA	14.4 months
3 - Low-intensity	5.9 months
4 - Supportive care therapy	2.1 months

A significant survival benefit using
frontline HMA



HR = 1.35, 95% CI, 1.10-1.65; P = .004

HR = 2.01, 95% CI, 1.53-2.62; P < .0001

HR = 2.94, 95% CI, 2.39-3.61; P < .0001